Atossa's Rare Pediatric Disease Designation for (Z)-endoxifen in neuromuscular diseases qualifies for a future PRV upon FDA approval SEATTLE, Feb. 5, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc.

Aro Biotherapeutics, a clinical-stage biotechnology company developing potent and tissue-targeted short-interfering RNA (siRNA) medicines, today announced interim data from a phase 1b study of ABX1100 ...

Flatfeet in babies are common and often temporary. However, understanding their causes and care is crucial for parents, as it ...

Examination revealed a soft, tan, slightly raised plaque with fine hairs growing within. Rubbing of the affected area showed piloerection, with mild bristling of the hairs.

Over half of newborns with severe spina bifida experience sleep-disordered breathing, an often overlooked early threat to ...

Cell and gene therapy company ENCell said on the 6th that its allogeneic umbilical cord-derived mesenchymal stem cell therapy candidate "EN001" received orphan drug designation (ODD) from the U.S.

The FDA has granted fast track designation to Dyscorban, Cumberland's therapy candidate for heart problems in people with ...

Albert Bourla: 2025 was a very good year for Pfizer Inc. I'm very pleased with strong execution to deliver and, frankly, overdeliver on our financial commitments. If successful, we will substantially ...

Even in remission, chronic inflammatory demyelinating polyneuropathy (CIDP) fatigue can be draining. Learn how to use the ...

Shareholder/Analyst Call February 5, 2026 3:30 PM ESTCompany ParticipantsRyan Watts - Co-Founder, President, CEO ...

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on developing new products for rare diseases, announced today that the U.S. Food and Drug Administration (FDA ...

Rosacea is a chronic skin condition affecting over 16 million Americans, causing facial redness, swelling, and discomfort.